Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 12

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
 discounted cash flow approach is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs. The calculation relies upon the probability of achieving the milestones and approximate timing of payment based on the terms of the arrangement. The following table discloses the summary of changes in the contingent consideration and assumed liabilities measured at fair value using Level 3 inputs (in thousands):Nine Months EndedSeptember 30, 2025Beginning of period$— Contingent consideration to sellers22,378 Assumed liabilities to third parties815 Change in fair value1,135 Balance at end of period$24,328 

4.     Restructuring 

On May 6, 2025, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $6.0 million associated with this plan, comprised primarily of severance-related costs, were recorded in the second quarter of 2025.The following table is a summary of restructuring costs for the nine months ended September 30, 2025 (in thousands):Severance and Benefits CostsStock-Based Compensation ExpenseTotalRestructuring charge$5,707 $314 $6,021 Cash payments made(5,632)— (5,632)Non-cash charge— (314)(314)Balance at September 30, 2025$75 $— $75 Restructuring costs of $0.4 million, $3.9 million and $1.7 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, in the Company's condensed consolidated 

10

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

statements of operations during the second quarter of 2025. The restructuring activities were substantially completed by the end of the third quarter of 2025.

5.    Other Financial Statement Information

Available-for-sale SecuritiesAvailable-for-sale securities consisted of the following (in thousands):September 30, 2025December 31, 2024Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value Amortized CostGross Unrealized GainsGross Unrealized LossesFair ValueFair Value MeasurementCash equivalents: Money market funds$399,256 $— $— $399,256 $322,012 $—